|
| | Tesamorelin (usan) Basic information |
| Product Name: | Tesamorelin (usan) | | Synonyms: | D06655;Tesamorelin (usan);TesamorelinAcetate;Hot selling Pharmaceutical peptides 2mg Tesamorelin 99%;Tesamorelin (usan) USP/EP/BP;TIANFUCHEM--218949-48-5---Tesamorelin (usan);Adipotide/FTTP;tesamorel | | CAS: | 218949-48-5 | | MF: | | | MW: | 0 | | EINECS: | 603-809-2 | | Product Categories: | 218949-48-5 | | Mol File: | Mol File | ![Tesamorelin (usan) Structure]() |
| | Tesamorelin (usan) Chemical Properties |
| | Tesamorelin (usan) Usage And Synthesis |
| Description | Tesamorelin (usan) consists of the 44 amino acid sequence of human growth hormone releasing factor (GRF), with a 3-hexenoyl group attached to its tyrosine N-terminal residue. It is a new growth hormone releasing factor analogue, which can not only restore normal growth hormone secretion in the body, but also reduce the increased visceral adipose tissue (VAT), improve blood lipid abnormalities and quality of life, and maintain glucose homeostasis in the body. | | Uses | Tesamorelin (usan) is indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy and is not recommended for weight loss. | | Side effects | Common adverse reactions of Tesamorelin (usan) include allergic reactions caused by growth hormone effects (such as arthralgia, peripheral edema, hyperglycemia), such as rash and urticaria, and erythema, itching, pain, urticaria and bleeding at the injection site. |
| | Tesamorelin (usan) Preparation Products And Raw materials |
|
